High Overexpression of the Human α-Galactosidase a Gene Driven by Its Promoter in Transgenic Mice: Implications for the Treatment of Fabry Disease
- 1 May 2002
- journal article
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 50 (3) , 185-192
- https://doi.org/10.2310/6650.2002.33432
Abstract
Background: Human α-galactosidase A (α-Gal A) is the lysosomal enzyme that cleaves α-galactosyl residues from glycoconjugates and is the deficient enzyme in Fabry disease. To date, there have been no studies on the regulation of this “housekeeping” gene. Methods: Transgenic mice were established with either 1) a 13.3-kilobase (kb) human genomic fragment that contained 246 bp of 5′- and approximately 2.8 kb of 3′- untranslated sequences, or 2) an “intronless” construct derived from the genomic sequence with the 5′ and 3′ flanking regions intact. Tissues that expressed high levels of α-Gal A activity were examined by light and electron microscopy. Results: Transgenic mice were generated with 2 and 12 copies of the genomic sequence (Lines 1 and 2) or about 60 copies of the intronless construct (Lines 3 and 4). In mice hemizygous for the genomic transgene (Lines 1 and 2), tissue α-Gal A activities were 12 to 155 times higher than those in the respective wild-type tissue, depending on tissue and transgene copy number. Of note, the high overexpression did not alter the cellular or subcellular cytoarchitecture. In contrast, α-Gal A activities expressed by mice that carried the intronless construct were only two- to sixfold more than in wild-type tissues in which the genomic transgene was highly expressed. Conclusions: The remarkably high levels of α-Gal A expression in transgenic mice carrying the intact genomic sequence versus the intronless construct suggested that the genomic sequence contained a strong intronic enhancer element. Identification of this regulatory element or elements may be useful in efforts to overexpress human α-Gal A for gene therapy endeavors. In addition, overexpression of human α-Gal A did not affect cellular morphology, which indicates that its overexpression in gene therapy endeavors should be safe.Keywords
This publication has 42 references indexed in Scilit:
- Detection of specific sequences among DNA fragments separated by gel electrophoresisPublished by Elsevier ,2006
- A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.Journal of Clinical Investigation, 1996
- A mutation in the 5′ untranslated region of the human α‐galactosidase A gene in high‐activity variants inhibits specific protein bindingFEBS Letters, 1995
- Fabry disease: Detection of gene rearrangements in the human α-Galactosidase A Gene by Multiplex PCR AmplificationHuman Mutation, 1993
- Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion.The Journal of cell biology, 1992
- Position-independent, high-level expression of the human β-globin gene in transgenic miceCell, 1987
- Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer ElementsScience, 1987
- CpG-rich islands and the function of DNA methylationNature, 1986
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Sanfilippo Disease Type B: Enzyme Replacement and Metabolic Correction in Cultured FibroblastsScience, 1973